Keyword Connections

•  David Haas
•  David Vigerust

•  Hannah Lee
•  Kelly Birdwell

•  Richard Ho

Resources

• No matching connections

Communities

• Richard Ho Laboratory

Publications

• Clopidogrel Pharmacogenetics - Why the Wait?
  Roden DM
  (2019) N Engl J Med 381: 1677-1678
• Estimation of the warfarin dose with clinical and pharmacogenetic data.
  International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA
  (2009) N Engl J Med 360: 753-64
• Cancer pharmacogenomics: strategies and challenges.
  Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ
  (2013) Nat Rev Genet 14: 23-34
• Pharmacogenomics: will the promise be fulfilled?
  Altman RB, Kroemer HK, McCarty CA, Ratain MJ, Roden D
  (2011) Nat Rev Genet 12: 69-73
• Pharmacogenomics.
  Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL
  (2019) Lancet 394: 521-532
• Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
  Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui CH, Evans WE, Relling MV
  (2011) Nat Genet 43: 237-41
• Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions.
  Karnes JH, Miller MA, White KD, Konvinse KC, Pavlos RK, Redwood AJ, Peter JG, Lehloenya R, Mallal SA, Phillips EJ
  (2019) Annu Rev Pharmacol Toxicol 59: 463-486
• Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
  Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S
  (2012) J Clin Oncol 30: 1415-21
• Interpreting P values in pharmacogenetic studies: a call for process and perspective.
  Maitland ML, Ratain MJ, Cox NJ
  (2007) J Clin Oncol 25: 4513-5
• Genetics and cardiovascular disease: a policy statement from the American Heart Association.
  Ashley EA, Hershberger RE, Caleshu C, Ellinor PT, Garcia JG, Herrington DM, Ho CY, Johnson JA, Kittner SJ, Macrae CA, Mudd-Martin G, Rader DJ, Roden DM, Scholes D, Sellke FW, Towbin JA, Van Eyk J, Worrall BB, American Heart Association Advocacy Coordinating Committee
  (2012) Circulation 126: 142-57
• Pharmacogenomics: the genetics of variable drug responses.
  Roden DM, Wilke RA, Kroemer HK, Stein CM
  (2011) Circulation 123: 1661-70
• Pharmacogenomics: personalizing pediatric heart transplantation.
  Van Driest SL, Webber SA
  (2015) Circulation 131: 503-12
• Clopidogrel and the concept of high-risk pharmacokinetics.
  Roden DM, Stein CM
  (2009) Circulation 119: 2127-30
• Applied pharmacogenomics in cardiovascular medicine.
  Weeke P, Roden DM
  (2014) Annu Rev Med 65: 81-94
• Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
  Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB
  (2006) Gastroenterology 130: 1793-806
• Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.
  White KD, Chung WH, Hung SI, Mallal S, Phillips EJ
  (2015) J Allergy Clin Immunol 136: 219-34; quiz 235
• Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
  Roden DM, Van Driest SL, Wells QS, Mosley JD, Denny JC, Peterson JF
  (2018) Circ Res 122: 1176-1190
• Cardiovascular pharmacogenomics.
  Roden DM, Johnson JA, Kimmel SE, Krauss RM, Medina MW, Shuldiner A, Wilke RA
  (2011) Circ Res 109: 807-20
• An exponential combination procedure for set-based association tests in sequencing studies.
  Chen LS, Hsu L, Gamazon ER, Cox NJ, Nicolae DL
  (2012) Am J Hum Genet 91: 977-86
• Genetic mechanisms of atrial fibrillation: impact on response to treatment.
  Darbar D, Roden DM
  (2013) Nat Rev Cardiol 10: 317-29
• Copy number polymorphisms and anticancer pharmacogenomics.
  Gamazon ER, Huang RS, Dolan ME, Cox NJ
  (2011) Genome Biol 12: R46
• Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.
  Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, Chasman DI, Zhou K, Arsenault BJ, Donnelly LA, Wiggins KL, Avery CL, Griffin P, Feng Q, Taylor KD, Li G, Evans DS, Smith AV, de Keyser CE, Johnson AD, de Craen AJ, Stott DJ, Buckley BM, Ford I, Westendorp RG, Slagboom PE, Sattar N, Munroe PB, Sever P, Poulter N, Stanton A, Shields DC, O'Brien E, Shaw-Hawkins S, Chen YD, Nickerson DA, Smith JD, Dubé MP, Boekholdt SM, Hovingh GK, Kastelein JJ, McKeigue PM, Betteridge J, Neil A, Durrington PN, Doney A, Carr F, Morris A, McCarthy MI, Groop L, Ahlqvist E, Welcome Trust Case Control Consortium, Bis JC, Rice K, Smith NL, Lumley T, Whitsel EA, Stürmer T, Boerwinkle E, Ngwa JS, O'Donnell CJ, Vasan RS, Wei WQ, Wilke RA, Liu CT, Sun F, Guo X, Heckbert SR, Post W, Sotoodehnia N, Arnold AM, Stafford JM, Ding J, Herrington DM, Kritchevsky SB, Eiriksdottir G, Launer LJ, Harris TB, Chu AY, Giulianini F, MacFadyen JG, Barratt BJ, Nyberg F, Stricker BH, Uitterlinden AG, Hofman A, Rivadeneira F, Emilsson V, Franco OH, Ridker PM, Gudnason V, Liu Y, Denny JC, Ballantyne CM, Rotter JI, Adrienne Cupples L, Psaty BM, Palmer CN, Tardif JC, Colhoun HM, Hitman G, Krauss RM, Wouter Jukema J, Caulfield MJ
  (2014) Nat Commun 5: 5068
• A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.
  Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME
  (2007) Proc Natl Acad Sci U S A 104: 9758-63
• Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci.
  Gamazon ER, Huang RS, Cox NJ, Dolan ME
  (2010) Proc Natl Acad Sci U S A 107: 9287-92
• A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation.
  Lin X, David CA, Donnelly JB, Michaelides M, Chandel NS, Huang X, Warrior U, Weinberg F, Tormos KV, Fesik SW, Shen Y
  (2008) Proc Natl Acad Sci U S A 105: 174-9
• Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
  Phillips EJ
  (2006) Clin Infect Dis 43: 103-5
• High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
  Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M, Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team
  (2008) Clin Infect Dis 46: 1111-8
• Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
  Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW, Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams
  (2015) Clin Infect Dis 60: 1860-3
• Developing novel treatments for mood disorders: accelerating discovery.
  Tamminga CA, Nemeroff CB, Blakely RD, Brady L, Carter CS, Davis KL, Dingledine R, Gorman JM, Grigoriadis DE, Henderson DC, B Innis RB, Killen J, Laughren TP, McDonald WM, M Murphy GM, Paul SM, Rudorfer MV, Sausville E, Schatzberg AF, Scolnick EM, Suppes T
  (2002) Biol Psychiatry 52: 589-609
• Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
  Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB
  (2011) Blood 118: 3163-71
• A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
  Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ
  (2008) Blood 112: 1022-7
• Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.
  Daneshjou R, Gamazon ER, Burkley B, Cavallari LH, Johnson JA, Klein TE, Limdi N, Hillenmeyer S, Percha B, Karczewski KJ, Langaee T, Patel SR, Bustamante CD, Altman RB, Perera MA
  (2014) Blood 124: 2298-305
• Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.
  Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF
  (2000) Cancer Res 60: 3440-4
• γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).
  Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA
  (2013) Clin Cancer Res 19: 721-30
• Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response.
  Asanuma Y, Xie HG, Stein CM
  (2005) Arthritis Rheum 52: 1349-59
• The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
  Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M, Clinical Pharmacogenomics Implementation Consortium (CPIC)
  (2012) Clin Pharmacol Ther 92: 112-7
• The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
  Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D
  (2011) Clin Pharmacol Ther 89: 784-5
• Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
  Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL, Clinical Pharmacogenetics Implementation Consortium
  (2012) Clin Pharmacol Ther 91: 734-8
• A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade.
  Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, Prasad HC, Byrne DW, Nair UB, Wood AJ, Stein CM
  (2003) Clin Pharmacol Ther 73: 366-71
• Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
  Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR, Clinical Pharmacogenetics Implementation Consortium
  (2011) Clin Pharmacol Ther 90: 328-32